Solid state forms of a quinazoline derivative and its use as a braf inhibitor
AssigneeIgnyta, Inc.
InventorsStephen J. BIERLMAIER, Ralph C. HALTIWANGER, Martin J. JACOBS
Life of this patent
Estimating the term…
Abstract
This application relates to various salts and solid state forms of Compound (I). This application also relates to pharmaceutical compositions and therapeutic uses of these materials and compositions.
Claims21
(canceled)
A method of treating cancer in a subject, comprising administering to said subject a therapeutically effective amount of a crystalline form of N-[3-[(6, 7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N′-[5-(2,2,2-trifluoro-1,1-dimethylethyl)-3-isoxazolyl]-urea, wherein said crystalline form is characterized by an x-ray powder diffraction pattern comprising a peak at a 2-theta value of about 4.8±0.2 degrees.
A method of treating cancer in a subject, comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a crystalline form of N-[3-[(6, 7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N′-[5-(2,2,2-trifluoro-1, 1-dimethylethyl)-3-isoxazolyl]-urea and a pharmaceutically acceptable excipient, wherein said crystalline form is characterized by an x-ray powder diffraction pattern comprising a peak at a 2-theta value of about 4.8±0.2 degrees.
Dependencies are inferred from the claim text.